RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Geni dell'angiogenesi indotti da ipossia: fattori di suscettibilità nella Sclerosi Laterale Amiotrofica ?
• 2 - Patogenesi molecolare delle malattie del motoneurone come tool per l’identificazione di nuovi approcci terapeutici biomolecolari e cellulari
• 3 - Aspetti biochimici e genetici del disturbo autistico.
• 4 - PROGRESSIONE DA MGUS A MIELOMA MULTIPLO: PATOGENESI MOLECOLARE, IDENTIFICAZIONE DI POTENZIALI MARCATORI PROGNOSTICI E SVILUPPO PRECLINICO DI RAZIONALI APPROCCI CHEMIOPREVENTIVI
• 5 - Basi molecolari, aspetti fisiopatologici e terapeutici delle malattie lisosomiali
• 6 - PRODUZIONE E CATABOLISMO DELLA BETA-AMILOIDE IN PAZIENTI CON MALATTIA DI ALZHEIMER E MILD COGNITIVE IMPAIRMENT: STUDI IN VITRO E MARKERS EX VIVO
• 7 - STUDI SUI FATTORI GENETICI ED IMMUNOLOGICI CHE REGOLANO IL DANNO TESSUTALE ED IL DECORSO CLINICO DELL'ARTRITE REUMATOIDE
• 8 - Paraparesi spastiche ereditarie: studio genetico, funzionale, clinico
• 9 - DISSEZIONE DEI FATTORI GENETICI E COMPRENSIONE DEI MECCANISMI RESPONSABILI DEL DIABETE AUTOIMMUNE
• 10 - BETA AMILOIDE: IL PRINCIPALE RESPONSABILE DELLA NEURODEGENERAZIONE NELLA MALATTIA DI ALZHEIMER O UN NUOVO NEUROMODULATORE?

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA
  • BIOLOGIA MOLECOLARE
  • BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Lazio

Bibliografia

1) Nussbaum RL, et al.Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003; 348:1356-64.
2) Selkoe DJ, et al.. Deciphering the genetic basis of Alzheimer’s disease. Annu Rev genomics Hum Genetic 2002; 3: 67-99.
3) Bennett DA, et al.Apolipoprotein E epsilon-4 allele, AD pathology, and the clinical expression of Alzheimer’s disease. Neurology 2003; 60(2): 246-52.
4) Klages JD, et al. APOE genotype, memory test performance, and the risk of Alzheimer’s disease in the Canadian study of health and aging. Dement Geriatr Cogn Disord 2003; 15(1):1-5.
5) McKhann G. et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939-974.
6) Castellani R, et al. Role of mitochondrial dysfunction in Alzheimer’s disease. J Neuroscience Res 2002; 70:357-360.
7) Butterfield DA, et al. Beta-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implication to Alzheimer’s disease. Biochem Byophys Res Commun. 1994;200:710-715.
8) Glabe C. intracellular mechanisms of amyloid accumulation in Alzheimer’s disease. J Mol Neurosci. 2001;17:137-145.
9) Hartmann T. Intracellular biology of Alzheimer’s disease amyloid beta peptide. Eur Arch Psychiatry Clin Neurosci 1999, 249:291-298.
10) Lovell MA, et al. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer’s Disease. Neurology 1998;51:1562-66.
11) Morishima Y, et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 2001;21:7551-7660.
12) Troy CM, et al. Beta-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem 2001;77:157-164.
13) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association, Washington DC 1994.
14) Carlesimo GA, et al. The Mental deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of Mental Deterioration Battery. Eur Neurol 1996; 36:378-384.
15) Cummings JL, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314
16) Folstein MF, et al. Mini Mental State: a pratical method for grading the cognitive state of patients for clinician. J Psychitr Res 1975;12: 189-198.
17) Lawton MP, Brody EM. Assessmrnt of older people: self-maintaining and instrumental activities of daily living. The Gerontologist 1969;9:179-86.
18) Pasqualetti P, et al. Mini-mental state examination and mental deterioration battery: analysis of the relationship and clinical implications. J Am Geriatr Soc 2002;50:1577-1581.
19)Sunderland T, et al. Decreased b-amyloid 1-42 and increaased Tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094-2103.
20)Sjogren M, et al. Advances in the detection of Alzheimer‘s disease-use of cerebrospinal fluid biomarkers. Clin Chim Acta 2003;332:1-10.
21)Blennow K, Hampel H. CSF markers for incipient Alzheimer‘s disease. Lancet Neurol 2003; 2: 605-613.
22)Desai P, et al. Genetic variation in the cholesterol 24-hydroxilase (CYP46) gene and the risk of Alzheimer‘s disease. Neurosc Lett 2002; 328: 9-12.
23) Martino, S., et al. (2002). Absence of metabolic cross-correction in Tay-Sachs cells: implication in gene therapy. J.Biol.Chem. 277, 20177-20184.
24) Bourgoin, C., et al.(2003)Widespread distribution of beta-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol. Gene Ther. 10, 1841-1849.
25) Walkley, S.U. (1998) Cellular pathology of lysosomal storage disorders. Brain Pathol. 8, 175-193.
26) Bucciantini M., et al. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfoldinf diseases. Nature 416, 507-511.
27) Cataldo, A.M., et al. (1995) Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for and early up-regulation of endosomal-lysosomal system. Neuron, 14, 671-680.
28) Adamec, E., et al. (2000) Up-regulation of the lysosomal system in experimental models of neuronal injury: implications for Alzheimer's disease. Neuroscience, 100, 663-675.
29) Mathews, P.M., et al. (2002) Alzheimer's disease related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolases distribution in beta amyloidogenesis. J. Biol.Chem. 277, 5299-5307.
30) Emiliani, C., et al.(2003) Up regulation of glycohydrolases in Alzheimer disease fibroblasts correlates with ras activation. J. Biol. Chem. 278, 38453-38460.
31) Sun, A., et al. (2003) P38 MAP kinase is activated at early stages in Alzheimer's disease brain.Exp.Neurol. 182, 394-405.
32) Connolly, G. (1998) Fibroblast models of neurological disorders: fluorescence measurements studies. Trends in Pharmacological Sciences 19, 171-177.
33) Citron M., et al. (1994). Excessive production of amyloid beta- protein by peripheral cells of symptomatic and pre-symptomatic patients carrying the Swedish familial Alzheimer's disease mutation. Proc. Natl. Acad. Sci. USA 91, 11993-11997.
34) Bains J.S. et al.(1997)Neurodegenerative disorders in human: the role of glutathione in oxidative stress mediated neuronal death. Brain Reasearch Review 25, 335-358
35) Revesz T, et al. Sporadic and familial cerebral amyloid angiopathies. Brain Pathology 2002; 12:343-357.
36) Rensink AAM, et al. Pathogenesis of cerebral amyloid angiopathy. Brain Research Review 2003; 43:207-223.
37) Natté R, et al. Dementia in hereditary cerebral hemorrhage with amyloidosis-dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. Annals of Neurology 2001; 50:765-771.
38) Rebeck GW, et al. The effects of AbPP mutations and APOE polymorphisms on cerebral amyloid angiopathy. Amyloid 2001; 8 (suppl 1): 43-47.
39) Knudsen KA, et al. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001; 56:537-539.
40) Sergeant N, et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. Journal of Neurochemistry 2003; 85:1581-1591.
41) Korolainen MA, et al. Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis 2002; 23: 3428-3433.
42) Choe LH, et al. Studies of potential cerebrospinal fluid markers for Alzheimer's disease. Electrophoresis 2002; 23:2247-2251.
43) Wiltfang J, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. Journal of Neurochemistry 2002; 81:481-496.
44) White, R. F. (1990). Emotional and cognitive correlates of multiple sclerosis. Journal of Neuropsychiatry, Neurosurgery, and Psychiatry 2: 422-428.
45) Brassington J.C. et al. Neuropsychological Aspects of Multiple Sclerosis Neuropsychology Review, 1998 Vol. 8, No. 2,
46) Maurelli, M., et al. (1992). Neuropsychological assessment in MS: Clinical, neurophysiological and neuroradiological relationships. Acta Neurologica Scandanavica 86: 124-128.
47) Ryan, L, et al. (1996). Patterns of cognitive impairment in relapsing-remitting multiple sclerosis and their relationship to neuropathology on magnetic resonance images. Neuropsychology 10: 176-193.
48) Lublin, F. D., et al. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46: 907-911.
49) Poser, C. M. (1994). The epidemiology of multiple sclerosis: A general overview. Annals of Neurology 36(Suppl. 2): 180-193.
50)Pandey A. et al. Proteomics to study genes and genomes Nature (2000), 405, 837-846

Parole Chiave

BIOCHIMICA CLINICA; MALATTIE NEURODEGENERATIVE; PROTEOMICA; SPETTROMETRIA DI MASSA; MALATTIA DI ALZHEIMER; ANGIOPATIA AMILOIDE; LIQUIDO CEREBROSPINALE; STRESS OSSIDATIVO; SCLEROSI MULTIPLA